Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Less Than Half of Incarcerated Population Receives Recommended Cancer Care

November 20, 2025
By Cary Gross, MD
Commentary
Video

A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.

Although about a third of the general population may not receive guideline-concordant care for cancer, more than half of patients incarcerated or recently released did not receive recommended care, highlighting severe gaps in accessing effective treatment among these populations.

In an interview with CancerNetwork®, Cary P. Gross, MD, professor of General Medicine and Epidemiology, as well as the founder and director of the Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center at the Yale School of Medicine, discussed findings from a study he coauthored and published in JAMA Network Open. The study explored the disparities in the quality of care between the general population and currently or recently incarcerated individuals undergoing treatment for their cancers.

Gross began by highlighting a relationship between history of incarceration and a lower quality of care among patients undergoing cancer treatment, with 49% of patients who were incarcerated at cancer diagnosis and 45% of those diagnosed within 1 year of release receiving guideline-concordant care vs 67% of the general population. Furthermore, Gross postulated that among all populations, there is a significant need for greater access to quality care, and that for the incarcerated population his team examined, underlying challenges related to accessing care and social determinants of health may could present as barriers.

Transcript:

What we found was that there was a relation between incarceration history and the quality of care. What we did was we matched [patients] who had been diagnosed with cancer in a certain time frame according to where they were diagnosed. What we found was that, broadly speaking, [for] people who were diagnosed during incarceration, about half of them received the care that was recommended for them [across] different types of cancer, breast, lung, prostate, et cetera; half of [patients] diagnosed during incarceration. But we found amongst people who were incarcerated but diagnosed afterward—the year after incarceration—only 45% were getting the recommended care. Both of those groups, 49% while incarcerated [and] 45% after incarceration, ended up having a lower likelihood of getting recommended care than people who are diagnosed out in the community; that group was 67%.

There are 2 main findings [or] 2 main inferences here. First, if you leave incarceration, leave that bucket to the side for a second, and focus on the broader population here in Connecticut, 67% [or] only two-thirds of [patients] are getting all of the care that’s recommended for them. [With] guideline-concordant care overall in the general population, there’s plenty of room for improvement. Now, the other 2 groups [with] current or recent incarceration, both of them had a lower quality of care, and that suggests that maybe it’s not the issue of whether someone’s currently incarcerated; maybe the underlying social challenges and challenges [with] accessing health care that may be associated with incarceration are driving some of these challenges to access and care.

Two take home points: there is a relation between incarceration and lower quality of care, but it’s not just because you are incarcerated. Again, because we think that the same factors that are associated with incarceration—such as less likelihood of having health insurance or being exposed to racism, a lack of feeling comfortable or welcome, or obtaining high quality care in the health system—could be barriers. The other major take home point is that in the larger population, there are gaps for everyone in getting the quality of care that [they] need.

Reference

Oladeru OT, Richman IB, Aminawung JA, et al. Incarceration and quality of cancer care. JAMA Netw Open. 2025;8(10):e2537400. doi:10.1001/jamanetworkopen.2025.37400

Recent Videos
Findings from David Rimm, MD, PhD, suggest that there may be an inverse relationship between HER2 and TROP2 expression among patients with breast cancer.
Tissue samples collected from patients with breast cancer during treatment may help explore therapy selection and predict toxicities.
The mechanism of CTO1681 may allow it to reduce the production of a broad range of proinflammatory cytokines in DLBCL.
Related Content
Advertisement

A Look Back on the Top 10 Oncology Interviews in 2025

A Look Back on the Top 10 Oncology Interviews in 2025

Ariana Pelosci
December 28th 2025
Article

Numerous clinicians spoke about breaking news, clinical trial updates, and the evolution of standard-of-care treatment throughout 2025.


Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Daniel C. McFarland, DO;Michelle Riba, MD
December 22nd 2025
Podcast

Daniel C. McFarland, DO; and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.


From KRAS inhibitors in metastatic CRC to radioligands and PET imaging agents in prostate cancer, dozens of oncologic approvals were reported in 2025.

Spotlighting the Top 10 FDA Oncology Approvals in 2025

Roman Fabbricatore
December 27th 2025
Article

From KRAS inhibitors in metastatic CRC to radioligands and PET imaging agents in prostate cancer, dozens of oncologic approvals were reported in 2025.


Why Sexual and Gender Minority Care Is an Oncologic Imperative

Why Sexual and Gender Minority Care Is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO; and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.


Top 10 Peer-Reviewed ONCOLOGY Articles Shaping Cancer Care in 2025

Top 10 Peer-Reviewed ONCOLOGY Articles Shaping Cancer Care in 2025

Ariana Pelosci
December 26th 2025
Article

Moving the needle in cancer research was an important focus for the journal ONCOLOGY in 2025.


Throughout 2025, our podcast highlighted experts who discussed the latest conference data, newly approved drugs, and other oncologic happenings.

Oncology On the Go Wrapped: The Top 10 Podcast Episodes of 2025

Russ Conroy
December 25th 2025
Article

Throughout 2025, our podcast highlighted experts who discussed the latest conference data, newly approved drugs, and other oncologic happenings.

Related Content
Advertisement

A Look Back on the Top 10 Oncology Interviews in 2025

A Look Back on the Top 10 Oncology Interviews in 2025

Ariana Pelosci
December 28th 2025
Article

Numerous clinicians spoke about breaking news, clinical trial updates, and the evolution of standard-of-care treatment throughout 2025.


Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Daniel C. McFarland, DO;Michelle Riba, MD
December 22nd 2025
Podcast

Daniel C. McFarland, DO; and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.


From KRAS inhibitors in metastatic CRC to radioligands and PET imaging agents in prostate cancer, dozens of oncologic approvals were reported in 2025.

Spotlighting the Top 10 FDA Oncology Approvals in 2025

Roman Fabbricatore
December 27th 2025
Article

From KRAS inhibitors in metastatic CRC to radioligands and PET imaging agents in prostate cancer, dozens of oncologic approvals were reported in 2025.


Why Sexual and Gender Minority Care Is an Oncologic Imperative

Why Sexual and Gender Minority Care Is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO; and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.


Top 10 Peer-Reviewed ONCOLOGY Articles Shaping Cancer Care in 2025

Top 10 Peer-Reviewed ONCOLOGY Articles Shaping Cancer Care in 2025

Ariana Pelosci
December 26th 2025
Article

Moving the needle in cancer research was an important focus for the journal ONCOLOGY in 2025.


Throughout 2025, our podcast highlighted experts who discussed the latest conference data, newly approved drugs, and other oncologic happenings.

Oncology On the Go Wrapped: The Top 10 Podcast Episodes of 2025

Russ Conroy
December 25th 2025
Article

Throughout 2025, our podcast highlighted experts who discussed the latest conference data, newly approved drugs, and other oncologic happenings.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.